Chest wall toxicity and Lung Stereotactic Ablative Radiotherapy V1.0

• Research type

  Research Study

• Full title

  Correlating Chest wall OAR doses with clinically relevant chest wall pain and rib fractures in the cohort of patients receiving Lung Stereotactic Ablative Radiotherapy

• IRAS ID

  315860

• Contact name

  Chunhui Li

• Contact email

  c.li@dundee.ac.uk

• Sponsor organisation

  University of Dundee

• Duration of Study in the UK

  0 years, 2 months, 26 days

• Research summary

  Stereotactic Ablative radiotherapy (SABR) is the preferred treatment technique for early stage non-small cell lung cancer. Using this technique, patients are planned to receive either 55Gy in 5 fractions or 60Gy in 8 fractions according to the established protocol. Due to the involved high dose and proximity of the tumour to the normal organs, complications from this technique are not always avoidable. In this retrospective study, chest wall toxicity is to be analysed in detail in co-relation to the predicted dose delivery from the treatment planning process.

• REC name

  HSC REC A

• REC reference

  22/NI/0111

• Date of REC Opinion

  22 Jun 2022

• REC opinion

  Further Information Favourable Opinion